SCHEMBL69127

SCHEMBL69127

O=C(O)C(c1ccccc1)C1CCCC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1E P28566 3/20 0.65
S1PR3 Q99500 3/20 0.65
LMNA P02545 3/20 0.65
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
MAPT P10636 1/20 0.65
CHRM3 P20309 4/20 0.59
HTT P42858 1/20 0.54
CYP3A4 P08684 3/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2D6 P10635 2/20 0.51
TSHR P16473 2/20 0.51
CHRM2 P08172 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51
CHRM1 P11229 1/20 0.51
DRD1 P21728 1/20 0.51
SLC6A2 P23975 1/20 0.51
ADRA1A P35348 1/20 0.51
OPRM1 P35372 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28622389 1.00 HTR1E (0.65) HTR1ES1PR3LMNAMEN1KMT2A
SCHEMBL12531975 0.98 HTR1E (0.63) HTR1ES1PR3LMNAMEN1KMT2A
SCHEMBL67219 0.98 HTR1E (0.63) HTR1ES1PR3LMNAMEN1KMT2A
Hydrochloric Acid SCHEMBL11526873 0.96 HTR1E (0.61) HTR1ES1PR3LMNAMEN1KMT2A
SCHEMBL67619 0.96 HTR1E (0.60) HTR1ES1PR3LMNAMEN1KMT2A
SCHEMBL66920 0.92 LMNA (0.54) HTR1ES1PR3LMNAMEN1KMT2A
Hydrochloric Acid SCHEMBL11359974 0.90 LMNA (0.53) HTR1ES1PR3LMNAMEN1KMT2A
SCHEMBL28373611 0.88 HTR1E (0.65) HTR1ES1PR3LMNAMEN1KMT2A
SCHEMBL4461851 0.88 HTR1E (0.53) HTR1ES1PR3LMNAMEN1KMT2A
SCHEMBL8875745 0.86 HTR1E (0.63) HTR1ES1PR3LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113788757-B Pentoxyverine citrate hapten, antigen, antibody, detection device and preparation method 广东江门中医药职业学院 2022-02-18 CN claimed
CN-113788757-A Pentoxyverine citrate hapten, antigen, antibody, detection device and preparation method 广东江门中医药职业学院 2021-12-14 CN claimed
CN-109457011-B Method for splitting alpha-cyclopentylphenylacetic acid enantiomer through stereoselective enzymatic hydrolysis 湖南理工学院 2021-09-07 CN claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 US claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US claimed
EP-1968980-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES, LTD. (IN) 2008-09-17 EP claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
WO-2007110782-A1 MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-10-04 WO claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
US-12551555-B2 Compositions and methods for potentiating immune activity KUMQUAT BIOSCIENCES INC. (US) 2026-02-17 US disclosed
US-4277372-A TITANIUM CHLORIDE DEPOSITED ON MAGNESIUM CHLORIDE SUPPORT HERCULES INCORPORATED (US) 1981-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS HTR1E 3059/4885S1PR3 4609/4885LMNA 4734/4885
US-12551555-B2 Compositions and methods for potentiating immune activity PTPRCAP, PTPN2, PTPRC HTR1E 4226/4885S1PR3 2652/4885LMNA 4799/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS HTR1E 3059/4885S1PR3 4609/4885LMNA 4734/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 HTR1E 2358/4885S1PR3 4760/4885LMNA 1769/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 HTR1E 4161/4885S1PR3 4846/4885LMNA 2024/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS HTR1E 3059/4885S1PR3 4609/4885LMNA 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.